Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Smoking reduces plasma bilirubin: Observational and genetic analyses in the Copenhagen General Population Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Brief smoking cessation intervention in relation to breast cancer surgery: a randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Is there a health benefit of reduced tobacco consumption? A systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Dianicline is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of drugs that includes varenicline and cytisine. Varenicline is efficacious for smoking cessation, while cytisine has not been studied systematically. The efficacy of dianicline has not been previously tested in an adequately powered study.
OriginalsprogEngelsk
TidsskriftNicotine & Tobacco Research
Vol/bind13
Udgave nummer1
Sider (fra-til)1-6
Antal sider6
ISSN1462-2203
DOI
StatusUdgivet - 1 jan. 2011

ID: 32785444